Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial
Authors:
- Lalantha LeelarathnaLLLalantha Leelarathna
- Shane W EnglishSEShane W English
- Hood ThabitHTHood Thabit
- Karen CaldwellKCKaren Caldwell
- Janet M AllenJAJanet M Allen
- Kavita KumareswaranKKKavita Kumareswaran
- Malgorzata E WilinskaMWMalgorzata E Wilinska
- Marianna NodaleMNMarianna Nodale
- Jasdip MangatJMJasdip Mangat
- Mark L EvansMEMark L Evans
- Rowan BurnsteinRBRowan Burnstein
- Roman HovorkaRHRoman Hovorka
Open Access
- 24 July 2013
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , R159
Abstract
Introduction: Closed-loop (CL) systems modulate insulin delivery according to glucose levels without nurse input. In a prospective randomized controlled trial, we evaluated the feasibility of an automated closed-loop approach based on subcutaneous glucose measurements in comparison with a local sliding-scale insulin-therapy protocol. Methods: Twenty-four critically ill adults (predominantly trauma and neuroscience patients) with hyperglycemia (glucose, ≥10 mM) or already receiving insulin therapy, were randomized to receive either fully automated closed-loop therapy (model predictive control algorithm directing insulin and 20% dextrose infusion based on FreeStyle Navigator continuous subcutaneous glucose values, n = 12) or a local protocol (n = 12) with intravenous sliding-scale insulin, over a 48-hour period. The primary end point was percentage of time when arterial blood glucose was between 6.0 and 8.0 mM. Results: The time when glucose was in the target range was significantly increased during closed-loop therapy (54.3% (44.1 to 72.8) versus 18.5% (0.1 to 39.9), P = 0.001; median (interquartile range)), and so was time in wider targets, 5.6 to 10.0 mM and 4.0 to 10.0 mM (P ≤ 0.002), reflecting a reduced glucose exposure >8 and >10 mM (P ≤ 0.002). Mean glucose was significantly lower during CL (7.8 (7.4 to 8.2) versus 9.1 (8.3 to 13.0] mM; P = 0.001) without hypoglycemia (M) during either therapy. Conclusions: Fully automated closed-loop control based on subcutaneous glucose measurements is feasible and may provide efficacious and hypoglycemia-free glucose control in critically ill adults. Trial Registration: ClinicalTrials.gov Identifier, NCT01440842.Keywords
This publication has 51 references indexed in Scilit:
- Technical Challenges and Clinical Outcomes of Using a Closed-Loop Glycemic Control System in the HospitalJournal of Diabetes Science and Technology, 2013
- Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target?The Journal of Clinical Endocrinology & Metabolism, 2009
- A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol studyIntensive Care Medicine, 2009
- Stress hyperglycaemiaThe Lancet, 2009
- Impact of shock requiring norepinephrine on the accuracy and reliability of subcutaneous continuous glucose monitoringIntensive Care Medicine, 2009
- Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study dataCanadian Medical Association Journal, 2009
- Towards closed-loop glycaemic controlBest Practice & Research Clinical Anaesthesiology, 2009
- Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery PatientsDiabetes Care, 2009
- Early blood glucose control and mortality in critically ill patients in Australia*Critical Care Medicine, 2009
- Intensive insulin therapy: enhanced Model Predictive Control algorithm versus standard careIntensive Care Medicine, 2008